Adverse Event Report
Unit 603 and 604, 6th Floor, Ryan Vanak Building, No. 18, West Side of Sheikh Baha'i Square, Tehran, Iran
(+98) 21 45395
Category: Nephrology and Hematology
TGlobulin25, produced by Kowsar Biotech Company, is a rabbit anti-human thymocyte immunoglobulin, the mechanism of action of which is to kill human T lymphocytes, thereby reducing the number of lymphocytes and weakening the immune system.
TGlobulin25 is a lyophilized powder consisting of human immunoglobulin G against human thymocytes at a concentration of 25 mg in each vial. The vials of this drug are dissolved in 5 ml of distilled water and infused with 0.9% sodium chloride.
This product is used for prophylaxis of acute transplant rejection, treatment of acute rejection (kidney, lung, heart and other organs), aplastic anemia, prophylaxis of transplant disease against acute and chronic host.
You should know about TGlobulin25:
This product should only be used by physicians who have experience with immunosuppressive drugs for the treatment of transplant patients. TGlobulin25 should be stored in the refrigerator (at 2 to 8 ° C) to prevent freezing.
Dosage Form of TGlobulin25™:
TGlobulin25TM is supplied for injection as a single-dose -5ml vial containing 25 mg of rabbit anti-thymocyte globulin (ATG) sterile lyophilized powder intended for reconstitution prior to intravenous administration.
Administration of TGlobulin25™:
IV: Infuse the first dose over at least 6 hours; subsequent doses may be infused over at least 4 hours. Infuse through a high-flow vein (CV Line). Reducing the infusion rate may minimize infusion reactions. Infusion rate may vary for off-label uses refer to specific protocol
Premedication of TGlobulin25™:
Premedication with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion may reduce the incidence of severity of infusion-related reactions. Reducing the infusion rate may minimize infusion reactions.
For adverse event report and contact with patient support unit
Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial
Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate-to-severe glabellar lines: A non-inferiority double blinded randomized controlled trial
Arta Pharmed Company, located in Tehran, Iran, is one of the new pharmaceutical companies that focuses on clinical studies, sales, marketing, market development, market access and scientific activities. This company, which was established in 2018, currently cooperates with more than 15 companies in various fields.
Unit 603 and 604, 6th Floor, Rayan Vanak Building, No. 18, West Side of Sheikh Bahaei Square, Tehran, Iran
Copyright © 2022 Arta Pharmed
Developed by "Arta Pharmed-Technical Dep."